Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N(G)-Iminoethylornithine (L-NIO) is a synthetic, experimental small molecule that belongs to the class of L-alpha-amino acids. It acts as a selective inhibitor of nitric oxide synthase 3 (NOS3, also known as endothelial nitric oxide synthase or eNOS). By inhibiting NOS3, it reduces the production of nitric oxide (NO), a key signaling molecule involved in vascular tone regulation and other physiological processes. The compound has been used primarily in research settings to study the role of NO in various biological systems and disease models[1][9]. There are no approved clinical indications for this drug.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N(G)-Iminoethylornithine.